Eli Lilly and Company (LLY) Expected to Announce Earnings on Thursday

Eli Lilly and Company (NYSE:LLY) is anticipated to announce its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Eli Lilly and Company to announce earnings of $5.68 per share and revenue of $22.58 billion for the quarter. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Individuals may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, October 29, 2026 at 10:00 AM ET.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. The company had revenue of $22.97 billion for the quarter, compared to analysts’ expectations of $20.82 billion. During the same quarter in the previous year, the business posted $6.31 EPS. The business’s quarterly revenue was up 47.7% on a year-over-year basis. On average, analysts expect Eli Lilly and Company to post $33.22 EPS for the current fiscal year and $47.23 EPS for the next fiscal year.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $1,283.52 on Wednesday. Eli Lilly and Company has a 52 week low of $809.63 and a 52 week high of $1,321.21. The stock’s 50-day moving average price is $1,191.27 and its 200-day moving average price is $1,088.34.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on LLY shares. Royal Bank Of Canada reissued an “outperform” rating and set a $1,500.00 target price on shares of Eli Lilly and Company in a research note on Monday, October 12th. Leerink Partners boosted their price target on Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 21st. Sanford C. Bernstein reissued an “outperform” rating and issued a $1,450.00 price objective on shares of Eli Lilly and Company in a research note on Monday. The Goldman Sachs Group reiterated a “buy” rating and issued a $1,413.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, October 20th. Finally, TD Cowen reiterated a “buy” rating and set a $1,250.00 price target on shares of Eli Lilly and Company in a report on Tuesday, September 22nd. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $1,320.25.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: A federal judge rejected Novo Nordisk’s request to block Lilly’s advertisements for its obesity treatments, finding insufficient evidence that the campaign caused meaningful or lasting harm to Novo’s sales. The decision allows Lilly to continue promoting its weight-loss portfolio, including Zepbound. Reuters article
• Positive Sentiment: New early-stage oncology data added to Lilly’s pipeline narrative. Olomorasib reportedly produced a 62% response rate in lung-cancer data, while Phase 1 results for sofe-M plus bevacizumab showed encouraging response and disease-control rates in ovarian cancer without major new safety signals. These results remain preliminary but could support longer-term growth expectations. Lung cancer results
• Positive Sentiment: Bernstein raised its price target for LLY to $1,450 from $1,385, reflecting continued confidence in Mounjaro, Zepbound and Lilly’s broader growth prospects. Commentary also notes that Lilly has significantly outperformed broader equities over the past five years. Bernstein price-target update
• Positive Sentiment: LillyDirect is working with Counsel Health on an AI-enabled, physician-led weight-management program, potentially expanding access and patient engagement around Lilly’s GLP-1 medicines. Counsel Health partnership
• Neutral Sentiment: International business chief Patrik Jonsson will retire at year-end after 36 years, with Ilya Yuffa becoming president of Lilly Global Markets on January 1, 2027. The planned transition is intended to support global expansion, but it introduces a leadership change investors will monitor. Lilly leadership announcement
• Neutral Sentiment: Lilly declared a quarterly dividend of $1.73 per share, payable December 10 to shareholders of record November 13. The 0.5% yield is modest, making the announcement more of a continuity signal than a major valuation catalyst. Dividend announcement
• Negative Sentiment: Ahead of earnings, analysts continue to flag pricing pressure, rising costs and intense competition from Novo Nordisk. Investors will focus on Mounjaro and Zepbound demand, patient growth, revenue realization and updated guidance; strong expectations increase the risk of a muted reaction if results or outlook fall short. Q3 earnings preview

Insider Activity

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 2,000 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. This represents a 56.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares in the company, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 13,500 shares of company stock valued at $15,958,170. 0.14% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.